drugset

drugset / Trial / NCT06692270

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

NCT06692270 ↗

Phase 2 Not yet recruiting 20 enrolled Fujian Cancer Hospital

NaSingle-groupOpen-labelTreatment

Summary

Tislelizumab in resectable esophageal squamous cell carcinoma

Timeline

Start: 2025-05-15
Primary completion: 2026-01-10
Completion: 2027-01-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tislelizumab	Monoclonal antibody	200 mg	—

Indications